NSC Research, Inc.

Johns Creek, Georgia 30024

7 studies enrolling now · 11 studies all time

What they study most

ASCVD, Atrial Fibrillation (AF), Cardiovascular Diseases, Cardiovascular Risk, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Heart Failure, Hypertension, Inflammation, Obesity, Overweight, Type2Diabetes

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable — Recruiting now
• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes — Recruiting now
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed